Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

Not specified

Conditions
Pulmonary Hypertension
Interventions
DRUG

sitaxsentan sodium

Trial Locations (26)

10032

Columbia Presbyterian Medical Center, New York

15213

University of Pittsburgh Medical Center, CHF/Transplantation Cardiology, Pittsburgh

21287

John Hopkins Hospital, Baltimore

27710

Duke University Medical Center, Durham

30033

Dekalb Medical Center, Decatur

30322

Emory University Hospital - McKelvey Lung Transplantation Center, Atlanta

30912

Medical College of Georgia, Augusta

37232

Vanderbilt University Medical Center, Nashville

43210

Division of Cardiology - The Ohio State University Medical Center, Columbus

44195

The Cleveland Clinic Foundation, Department of Pulmonary and Critical Care, Cleveland

48109

University of Michigan Hospital, Division of Cardiology, Ann Arbor

53215

University of Wisconsin Medical School, Milwaukee

55905

Mayo Clinic - Division of Cardiovascular Disease, Rochester

60612

Rush Heart Institute, Center for Pulmonary Heart Disease, Rush-Presbyterian-St. Luke's Medical Center, Chicago

70112

LSU - School of Medicine, New Orleans

77030

Baylor College of Medicine Pulmonary & Critical Care Section, Houston

80218

The Children's Hospital, Denver

80262

University of Colorado/ Health Science Center, Denver

90033

University of Southern California Hospital, Ambulatory Health Sciences, Los Angeles

90502

Harbor-UCLA Medical Center, Torrance

94143

University of California, San Francisco, San Francisco

97201

Oregon Health Sciences, Portland

04102

Maine Medical Center, Portland

02114

Massachusetts General Hospital, Boston

02903

Pulmonary Division - Rhode Island Hospital, Providence

H3T 1E2

SMBD Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ICOS Corporation

INDUSTRY

collaborator

Texas Biotechnology Corporation

INDUSTRY

lead

ICOS-Texas Biotechnology

INDUSTRY